Form 4 for GYRE GYRE THERAPEUTICS, INC.

Accepted 2024-12-26 00:00:00 ET · period of report 2024-12-23 · accession 0001140361-24-050413 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
MTI	2024-12-26	2024-12-23+	GYRE	Ma Songjiang	Pres, Dir	S - Sale	$12.10	-4,000	2.93M	-0.1%	-$48.4K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2024-12-23	S	D	296	$12.44	2,932,467	I By Spouse	—	—	(F3) The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.41 to $12.48. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
2	Common	Common Stock	2024-12-24	S	D	2,000	$11.93	2,930,467	I By Spouse	—	—	(F4) The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.76 to $12.09. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
3	Common	Common Stock	2024-12-23	S	D	1,704	$12.24	2,932,763	I By Spouse	—	—	(F2) The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.40 to $12.39. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.